NL-OMON42086已完成不适用
A single-center, randomized, open-label, 3 way crossover study to evaluate the single and multiple dose pharmacokinetic profile of HP-5000 compared to PENNSAID® 2% in healthy volunteers - HP-5000 / PENNSAID 2% 3 way crossover study
PRA Health Sciences0 个研究点目标入组 18 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •healthy volunteers
- •18 - 65 years, inclusive
- •18 - 30 kg/m2, inclusive
排除标准
- •Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 30 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A single-center, open-label, randomized, 3-way crossover study to compare the rate and extent of Rivastigmine absorption from two different formulations of 7 day Rivastigmine transdermal systems (7-day RTS) with 24-hour Exelon® patches applied daily for 7 days in healthy male and female subjects.10012272DementiaNL-OMON40916oven Pharmaceuticals, Inc.18
已完成
不适用
A single-center, open-label, randomized, 3-way crossover study to evaluate the pharmacokinetic profile and tolerability of Flurbiprofen following administration of two Flurbiprofen transdermal formulations compared to Yakuban Tape® in healthy subjectsNL-OMON40944oven Pharmaceuticals, Inc.18
招募中
Unknown
An open-label study comparing the blood concentrations of Irinotecan Liposomal Injection at different times in patients with metastatic adenocarcinoma of the pancreas, previously treated with gemcitabine.CTRI/2023/08/056699Mylan Laboratories Ltd.
进行中（未招募）
不适用
A Phase III, Randomized, Open-label, Single-center Study to Evaluate the Safety and Immunogenicity of a FLUAD-H5N1 Influenza Vaccine in Adult Subjects Using Four Different Vaccination SchedulesEUCTR2008-003008-72-CZovartis Vaccines and Diagnostics S.r.l240
进行中（未招募）
1 期
Evaluation of efficacy and safety of DCVAC/OvCa (therapeutic ovarian cancer vaccine) in women with newly diagnoses ovarian cancerepithelial ovarian carcinomaMedDRA version: 17.1Level: PTClassification code 10061328Term: Ovarian epithelial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001322-26-DESOTIO a.s.90